Best price Trastuzumab Herceptin、Herclon Cure cancer 180288-69-1 Treatment of gastric cancer CAS NO.180288-69-1

★ Humanized monoclonal antibodies derived from recombinant DNA

★ Can be used as a single drug, light adverse reactions, good tolerance, can be treated in the outpatient clinic

★ The effect of Herceptin is significant, and the median remission time is long

Each bottle contains 440 mg of concentrated trastuzumab powder, which is white to light yellow freeze-dried powder, and can be prepared into a solution for intravenous infusion. The concentration of trastuzumab after dissolution was 21 mg/mL.

Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively acts on the extracellular site of human epidermal growth factor receptor-2 (HER2). The antibody is of IgGl type and contains the human framework region and the complementary determinant region of the mouse anti-P185 HER2 antibody that binds to HER-2.

Humanized anti-HER2 antibodies are produced from mammalian cells (CHO) suspended in a sterile medium and purified by affinity chromatography and ion exchange, including special removal procedures for virus inactivation. National hamster ovary cells

The HER2 proto-oncogene or C-erbB2 encodes a single receptor-like transmembrane protein with a molecular weight of 185kDa that is structurally related to the epidermal growth factor receptor. HER2 overexpression is observed in 25% to 30% of patients with primary breast cancer. Amplification of the HER2 gene results in increased expression of the HER2 protein on the surface of these tumor cells, leading to activation of the HER2 receptor.

Studies have shown that tumor patients with overexpression of HER2 have shorter disease-free survival than those without overexpression. Overexpression of HER2 can be diagnosed by immunohistochemical-based evaluation of tumor tissue mass, ELISA of tissue or plasma samples, or fluorescence in situ hybridization (FISH).

Trastuzumab has been shown to inhibit the proliferation of HER2-overexpressed tumor cells both in vitro and in animal studies. In addition, trastuzumab is a potential mediator of antibody dependent cell-mediated cytotoxic reactions (ADCC). In in vitro studies, trastuzumab mediated ADCC was shown to be preferentially produced in HER2-overexpressing cancer cells compared to HER2-non-overexpressing cancer cells.

Indications for Herceptin

For the treatment of HER2-overexpressed metastatic breast cancer: metastatic breast cancer that has been treated with one or more chemotherapy regimens as a single agent; Combined with taxoid drugs for the treatment of metastatic breast cancer that has not received chemotherapy.

Usage and dosage of Trastuzumab

When used as a single drug or in combination with other chemotherapeutics, it is recommended to administer the following initial loads and maintenance doses.

Initial load dose: The recommended initial load is 4 mg/kg, intravenously administered within 90 minutes. The patient should be observed for fever, chills, or other infusion-related symptoms. These symptoms can be controlled by stopping the infusion, and the infusion can be continued after the symptoms have disappeared.

Maintenance dose: 2 mg/kg per week is recommended. If the initial load is tolerable, this dose can be administered within 30 minutes.

Do not push or intravenous infusion.

Course of treatment This drug can be used until the disease progresses. According to foreign market research data, the average patient receiving treatment is about 24 to 26 weeks of continuous use

This drug has not been used in reduced dose clinical trials. Patients can continue to use it during reversible chemotherapy-induced myelosuppression, and special guidance is required on whether to reduce or continue the use of chemotherapy doses.

Special patients: Data showed no effect on the distribution of the drug by age or plasma creatinine concentration. In clinical trials, older patients did not reduce their use.